ShangPharma opens pilot plant in Shanghai
For pharma development and cGMP manufacturing
The new multi-purpose pharmaceutical development and cGMP manufacturing facility will allow ShangPharma to support its clients Phase II and Phase III trials, expanding its service offering to include process and formulation r&d, analytical method development and validation, and cGMP manufacturing of intermediates and APIs.
Previously the CRO/CMO provided clients with materials for early discovery and GLP toxicology testing and Phase I clinical trials.
ShangPharma said it might further expand its manufacturing facilities if there is demand for commercial manufacturing of FDA- or EMEA-approved drugs.
The Fengxian facility will operate as a wholly owned subsidiary of the company under the name China Gateway Pharmaceutical Development Co. It includes a pilot plant that supports six separate bays with reactor capacities ranging from 200 to 3,000 litres and other speciality bays with reactor capacities ranging from 50 to 2000 litres for high temperature, cryogenics, highly toxic and pressurised reactions, including hydrogenation.
The company said there are also two cleanroom suites rated at Class 100,000 for isolation, 10 kilo-lab suites for bothnon-cGMP and cGMP manufacturing, as well as a large r&d laboratory for analytical, formulation and process development activities.
In addition, there are separate buildings for utilities, materials management, warehouse storage and waste water treatment with room for further expansion to support commercial manufacturing activities.
Testing of raw materials, intermediates and final products will be carried out at the site. An independent quality assurance department will ensure that materials are manufactured in accordance with cGMP requirements and that established standard operating procedures are followed, the firm said.
You may also like
Trending Articles
You may also like
Manufacturing
![SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs]()
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs
Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Portable gas detection in the pharmaceutical sector]()
Portable gas detection in the pharmaceutical sector
Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
![New legal duties for QPs in decentralised manufacturing]()
New legal duties for QPs in decentralised manufacturing
In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Manufacturing
![FDA escalates action against Dabur India over systemic data-integrity and cGMP failures]()
FDA escalates action against Dabur India over systemic data-integrity and cGMP failures
The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
Manufacturing
![DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction]()
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction
The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows
Regulatory
![Aravax secures FDA Fast Track designation for peanut allergy immunotherapy PVX108]()
Aravax secures FDA Fast Track designation for peanut allergy immunotherapy PVX108
The designation accelerates development of the peptide-based immunotherapy, which is designed to retrain immune tolerance to peanuts without triggering acute allergic reactions — with Phase II data expected later this year